Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Celltrion Launches Tocilizumab Biosimilar in Korea

Jun 2, 2025

On 2 June 2025, ChosunBiz reported that Celltrion has launched Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), in Korea. Avtozma® was approved by Korea’s Ministry of Food and Drug Safety…

Sandoz Launches First Denosumab Biosimilars in US

Jun 2, 2025

On 2 June 2025, Sandoz announced its US launch of Wyost® and Jubbonti®, biosimilars to Amgen’s Xgeva® and Prolia® (denosumab), respectively. Wyost® and Jubbonti® are the first and only…

Sandoz’s Denosumab Biosimilars First Approved in New Zealand

May 29, 2025

On 29 May 2025, New Zealand’s Medsafe approved Sandoz’s Jubbonti® and Wyost®, biosimilars to Amgen’s Prolia® and Xgeva (denosumab), respectively.  This makes Sandoz’s Jubbonti® and Wyost® the first denosumab biosimilars approved in New Zealand.

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here